PERCENT OF PATIENTS ATTAINING EUROPEAN GUIDELINES LDL-C GOAL OF < 2 MMOL/L IN 3 STUDIES EVALUATING EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN OR ROSUVASTATIN
Brudi, P., Lantz, K., Polis, A., Tershakovec, A.Volume:
9
Language:
english
Journal:
Atherosclerosis Supplements
DOI:
10.1016/s1567-5688(08)70753-0
Date:
May, 2008
File:
PDF, 148 KB
english, 2008